Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2024.09.038 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Qing-Bin Zeng und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China; Key Laboratory of Neurogenetics and Channelopathies of Guangdong Provi…. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Electroconvulsive Therapy, Ketamine, Propofol. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Electroconvulsive therapy (ECT) is a commonly used alternative for treatment-resistant depression (TRD). Although esketamine has a rapid pharmacological antidepressant action, it has not been studied as an ECT anesthetic. The objective of this study was to compare the efficacy and safety of esketamine with propofol when both are used as ECT anesthetic agents. METHODS: Forty patients with TRD were assigned to one of two arms in a double-blind, randomized controlled trial: esketamine or propofol anesthesia for a series of eight ECT sessions. Using a non-inferiority design, the primary outcome was the reduction in HAMD-17 depressive symptoms. The other outcomes were: rates of response and remission, anxiety, suicidal ideation, cognitive function, and adverse events. These were compared in an intention-to-treat analysis. RESULTS: Esketamine-ECT was non-inferior to propofol-ECT for reducing TRD symptoms after 8 sessions (adjusted Δ = 2.0, 95 % CI: -1.2-5.1). Compared to propofol-ECT, esketamine-ECT also had higher depression response (80 % vs. 70 %; p = .06) and remission (65 % vs. 55 %; p = .11) rates but non-inferiority was not established. In four components of cognitive function (speed of processing, working memory, visual learning, and verbal learning) esketamine-ECT was non-inferior to propofol-ECT. The results for anxiety, suicidal ideation, and adverse events (all p's > .05) were inconclusive. CONCLUSION: Esketamine was non-inferior to propofol when both are used as anesthetics for TRD patients undergoing ECT. Replication studies with larger samples are needed to examine the inconclusive results. REGISTRATION NUMBER: ChiCTR2000033715.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China; Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical Universi…
- The Third People's Hospital of Foshan, Foshan, Guangdong, China.
- Department of Psychiatry, University of Saskatchewan, Saskatoon, SK, Canada.
- Unit of Psychiatry, Department of Public Health and Medicinal Administration, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China; Centre for Cognitive and Brain Scienc…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zeng, Q. B., Zou, D. C., Huang, X. B., Shang, D. W., Huang, X., Yang, X. H., Ning, Y. P., Balbuena, L., Xiang, Y. T., & Zheng, W. (2025). Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.09.038
Vancouver
Zeng QB, Zou DC, Huang XB, Shang DW, Huang X, Yang XH, et al. Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2024.09.038
BibTeX
@article{Zeng2025,
author = {Zeng, Qing-Bin and Zou, De-Cheng and Huang, Xing-Bing and Shang, De-Wei and Huang, Xiong and Yang, Xin-Hu and Ning, Yu-Ping and Balbuena, Lloyd and Xiang, Yu-Tao and Zheng, Wei},
title = {Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2024.09.038}
}
EUVIMED